Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 923 full-time employees. The company went IPO on 2018-10-31. The firm's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The company has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The firm also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The firm's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. The company has minority ownership in Atlas Data Storage, Inc.
How did TWST's recent EPS compare to expectations?
The most recent EPS for Twist Bioscience Corp is $-0.59, beating expectations of $-0.48.
How did Twist Bioscience Corp TWST's revenue perform in the last quarter?
Twist Bioscience Corp revenue for the last quarter is $-0.59
What is the revenue estimate for Twist Bioscience Corp?
According to 11 of Wall street analyst, the revenue estimate of Twist Bioscience Corp range from $124.32M to $113.97M
What's the earning quality score for Twist Bioscience Corp?
Twist Bioscience Corp has a earning quality score of A-/60.77337. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Twist Bioscience Corp report earnings?
Twist Bioscience Corp next earnings report is expected in 2026-08-02
What are Twist Bioscience Corp's expected earnings?
Twist Bioscience Corp expected earnings is $109.81M, according to wall-street analysts.
Did Twist Bioscience Corp beat earnings expectations?
Twist Bioscience Corp recent earnings of $110.71M beat expectations.